Upregulation of chemokine receptor CCR10 is essential for glioma proliferation, invasion and patient survival

Oncotarget

Volumn 5, Issue 16, 2014, Pages 6576-6583

  Chen, Lingchao ^a   Liu, Xing ^b   Zhang, Hai Yan ^c   Du, Wenzong ^b   Qin, Zhiyong ^a   Yao, Yu ^a   Mao, Ying ^a   Zhou, Liangfu ^a  

^a FUDAN UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Akt pathway; CCR10; Glioma

Indexed keywords

CHEMOKINE RECEPTOR CCR10; CUTANEOUS T CELL ATTRACTING CHEMOKINE; CCR10 PROTEIN, HUMAN; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BRAIN TUMOR; GENETIC TRANSFECTION; GENETICS; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; SURVIVAL; UPREGULATION; XENOGRAFT;

ANIMALS; BRAIN NEOPLASMS; CELL PROLIFERATION; GLIOBLASTOMA; HETEROGRAFTS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, CCR10; SURVIVAL ANALYSIS; TRANSFECTION; UP-REGULATION;

EID: 84907066413     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2134     Document Type: Article

References (33)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England journal of medicine. 2005; 352(10):987-996.
2. Butowski NA, Sneed PK and Chang SM. Diagnosis and treatment of recurrent high-grade astrocytoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006; 24(8):1273-1280.
3. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY and Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA: a cancer journal for clinicians. 2010; 60(3):166-193.
4. Chen L, Zhang W, Yan W, Han L, Zhang K, Shi Z, Zhang J, Wang Y, Li Y, Yu S, Pu P, Jiang C, Jiang T and Kang C. The putative tumor suppressor miR-524-5p directly targets Jagged-1 and Hes-1 in glioma. Carcinogenesis. 2012; 33(11):2276-2282.
5. Chen L, Zhang J, Feng Y, Li R, Sun X, Du W, Piao X, Wang H, Yang D, Sun Y, Li X, Jiang T, Kang C, Li Y and Jiang C. MiR-410 regulates MET to influence the proliferation and invasion of glioma. The international journal of biochemistry & cell biology. 2012; 44(11):1711-1717.
6. Chen L, Han L, Zhang K, Shi Z, Zhang J, Zhang A, Wang Y, Song Y, Li Y, Jiang T, Pu P, Jiang C and Kang C. VHL regulates the effects of miR-23b on glioma survival and invasion via suppression of HIF-1alpha/VEGF and beta-catenin/Tcf-4 signaling. Neuro-oncology. 2012; 14(8):1026-1036.
7. Chen L, Wang X, Wang H, Li Y, Yan W, Han L, Zhang K, Zhang J, Wang Y, Feng Y, Pu P, Jiang T, Kang C and Jiang C. miR-137 is frequently down-regulated in glioblastoma and is a negative regulator of Cox-2. Eur J Cancer. 2012; 48(16):3104-3111.
8. Chen L, Zhang A, Li Y, Zhang K, Han L, Du W, Yan W, Li R, Wang Y, Wang K, Pu P, Jiang T, Jiang C and Kang C. MiR-24 regulates the proliferation and invasion of glioma by ST7L via beta-catenin/Tcf-4 signaling. Cancer letters. 2013; 329(2):174-180.
9. Murphy PM. International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature. Pharmacological reviews. 2002; 54(2):227-229.
10. Balkwill F. Cancer and the chemokine network. Nature reviews Cancer. 2004; 4(7):540-550.
11. Roussos ET, Condeelis JS and Patsialou A. Chemotaxis in cancer. Nature reviews Cancer. 2011; 11(8):573-587.
12. Kulbe H, Levinson NR, Balkwill F and Wilson JL. The chemokine network in cancer-much more than directing cell movement. The International journal of developmental biology. 2004; 48(5-6):489-496.
13. Balkwill FR. The chemokine system and cancer. The Journal of pathology. 2012; 226(2):148-157.
14. Li T, Li H, Wang Y, Harvard C, Tan JL, Au A, Xu Z, Jablons DM and You L. The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma. The Journal of pathology. 2011; 223(4):519-530.
15. Ou DL, Chen CL, Lin SB, Hsu CH and Lin LI. Chemokine receptor expression profiles in nasopharyngeal carcinoma and their association with metastasis and radiotherapy. The Journal of pathology. 2006; 210(3):363-373.
16. Ping YF, Yao XH, Jiang JY, Zhao LT, Yu SC, Jiang T, Lin MC, Chen JH, Wang B, Zhang R, Cui YH, Qian C, Wang J and Bian XW. The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling. The Journal of pathology. 2011; 224(3):344-354.
17. Munson JM, Bellamkonda RV and Swartz MA. Interstitial flow in a 3D microenvironment increases glioma invasion by a CXCR4-dependent mechanism. Cancer research. 2013; 73(5):1536-1546.
18. Hattermann K, Held-Feindt J, Ludwig A and Mentlein R. The CXCL16-CXCR6 chemokine axis in glial tumors. Journal of neuroimmunology. 2013; 260(1-2):47-54.
19. Choi YH, Burdick MD, Strieter BA, Mehrad B and Strieter RM. CXCR4, but not CXCR7, discriminates metastatic behavior in non-small cell lung cancer cells. Molecular cancer research: MCR. 2013.
20. Deutsch AJ, Aigelsreiter A, Steinbauer E, Fruhwirth M, Kerl H, Beham-Schmid C, Schaider H and Neumeister P. Distinct signatures of B-cell homeostatic and activation-dependent chemokine receptors in the development and progression of extragastric MALT lymphomas. The Journal of pathology. 2008; 215(4):431-444.
21. Chen L, Huang K, Han L, Shi Z, Zhang K, Pu P, Jiang C and Kang C. beta-catenin/Tcf-4 complex transcriptionally regulates AKT1 in glioma. International journal of oncology. 2011; 39(4):883-890.
22. Kai H, Kadono T, Kakinuma T, Tomita M, Ohmatsu H, Asano Y, Tada Y, Sugaya M and Sato S. CCR10 and CCL27 are overexpressed in cutaneous squamous cell carcinoma. Pathology, research and practice. 2011; 207(1):43-48.
23. Monteagudo C, Ramos D, Pellin-Carcelen A, Gil R, Callaghan RC, Martin JM, Alonso V, Murgui A, Navarro L, Calabuig S, Lopez-Guerrero JA, Jorda E and Pellin A. CCL27-CCR10 and CXCL12-CXCR4 chemokine ligand-receptor mRNA expression ratio: new predictive factors of tumor progression in cutaneous malignant melanoma. Clinical & experimental metastasis. 2012; 29(6):625-637.
24. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(43):15545-15550.
25. Dehm SM and Bonham K. SRC gene expression in human cancer: the role of transcriptional activation. Biochemistry and cell biology = Biochimie et biologie cellulaire. 2004; 82(2):263-274.
26. Yu JC, Li W, Wang LM, Uren A, Pierce JH and Heidaran MA. Differential requirement of a motif within the carboxyl-terminal domain of alpha-platelet-derived growth factor (alpha PDGF) receptor for PDGF focus forming activity chemotaxis, or growth. The Journal of biological chemistry. 1995; 270(13):7033-7036.
27. Murakami T, Cardones AR, Finkelstein SE, Restifo NP, Klaunberg BA, Nestle FO, Castillo SS, Dennis PA and Hwang ST. Immune evasion by murine melanoma mediated through CC chemokine receptor-10. The Journal of experimental medicine. 2003; 198(9):1337-1347.
28. Notohamiprodjo M, Segerer S, Huss R, Hildebrandt B, Soler D, Djafarzadeh R, Buck W, Nelson PJ and von Luettichau I. CCR10 is expressed in cutaneous T-cell lymphoma. International journal of cancer Journal international du cancer. 2005; 115(4):641-647.
29. Simonetti O, Goteri G, Lucarini G, Filosa A, Pieramici T, Rubini C, Biagini G and Offidani A. Potential role of CCL27 and CCR10 expression in melanoma progression and immune escape. Eur J Cancer. 2006; 42(8):1181-1187.
30. Harasawa H, Yamada Y, Hieshima K, Jin Z, Nakayama T, Yoshie O, Shimizu K, Hasegawa H, Hayashi T, Imaizumi Y, Ikeda S, Soda H, Atogami S, Takasaki Y, Tsukasaki K, Tomonaga M, et al. Survey of chemokine receptor expression reveals frequent co-expression of skin-homing CCR4 and CCR10 in adult T-cell leukemia/lymphoma. Leukemia & lymphoma. 2006; 47(10):2163-2173.
31. Kuhnelt-Leddihn L, Muller H, Eisendle K, Zelger B and Weinlich G. Overexpression of the chemokine receptors CXCR4, CCR7, CCR9, and CCR10 in human primary cutaneous melanoma: a potential prognostic value for CCR7 and CCR10? Archives of dermatological research. 2012; 304(3):185-193.
32. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E and Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001; 410(6824):50-56.
33. Homey B, Wang W, Soto H, Buchanan ME, Wiesenborn A, Catron D, Muller A, McClanahan TK, Dieu-Nosjean MC, Orozco R, Ruzicka T, Lehmann P, Oldham E and Zlotnik A. Cutting edge: the orphan chemokine receptor G protein-coupled receptor-2 (GPR-2, CCR10) binds the skin-associated chemokine CCL27 (CTACK/ALP/ILC). J Immunol. 2000; 164(7):3465-3470.